Ndai Asinamai M, Allen Brandon R, Wynn Tung T, Rajasekhar Anita, Saqr Ziad, Sandeli Ina, Vouri Scott M, Reise Rachel
Department of Pharmaceutical Outcomes and Policy College of Pharmacy University of Florida Gainesville Florida USA.
University of Florida Health Physicians Gainesville Florida USA.
J Am Coll Emerg Physicians Open. 2024 May 2;5(3):e13168. doi: 10.1002/emp2.13168. eCollection 2024 Jun.
This study aimed to assess the effectiveness of a continuous quality improvement initiative at the University of Florida Health Physicians practice in reducing the time to administer factor replacement therapy (FRT) for hemophilia patients presenting with bleeding in the emergency department (ED).
The study, a quasi-experimental, interventional design, was conducted between January 2020 and January 2023. The intervention, implemented in September 2021, involved training ED physicians, creating a specialized medication order set within the electronic health record (EHR), and a rapid triage system. The effectiveness was measured by comparing the time from ED arrival to factor administration before and after the intervention and benchmarking it against the National Bleeding Disorders Foundation's Medical and Scientific Advisory Council (MASAC)-recommended 1-hour timeline for factor administration. An interrupted time series (ITS) analysis with a generalized least squares model assessed the intervention's impact.
A total of 43 ED visits (22 pre-intervention and 21 post-intervention) were recorded. Post-intervention, the average time from ED arrival to factor administration decreased from 5.63 to 3.15 hours. There was no significant increase (27% vs. 29%) in the patients receiving factor within 1-hour of ED arrival. The ITS analysis predicted a 20-hour reduction in the average quarterly time to administer factor by the end of the study, an 84% decrease.
The quality improvement program decreased the time to administer FRT for patients with hemophilia in the ED. However, the majority of patients did not achieve the 1-hour MASAC-recommended timeline for factor administration after ED arrival.
本研究旨在评估佛罗里达大学健康医师诊所开展的持续质量改进举措在缩短急诊科(ED)中出现出血症状的血友病患者接受凝血因子替代疗法(FRT)的给药时间方面的效果。
该研究采用准实验性干预设计,于2020年1月至2023年1月期间进行。2021年9月实施的干预措施包括培训急诊科医生、在电子健康记录(EHR)中创建专门的用药医嘱集以及一个快速分诊系统。通过比较干预前后从患者抵达急诊科到给予凝血因子的时间,并将其与国家出血性疾病基金会医学与科学咨询委员会(MASAC)推荐的1小时凝血因子给药时间基准进行对比,来衡量干预措施的效果。采用广义最小二乘法模型进行中断时间序列(ITS)分析,以评估干预措施的影响。
共记录了43次急诊科就诊情况(干预前22次,干预后21次)。干预后,从患者抵达急诊科到给予凝血因子的平均时间从5.63小时降至3.15小时。在患者抵达急诊科后1小时内接受凝血因子治疗的患者比例没有显著增加(分别为27%和29%)。ITS分析预测,到研究结束时,平均每季度给予凝血因子的时间将减少20小时,降幅为84%。
质量改进计划缩短了急诊科中血友病患者接受FRT的给药时间。然而,大多数患者在抵达急诊科后并未达到MASAC推荐的1小时凝血因子给药时间标准。